Fig. 2
Subchronic TPA-023 treatment prevented and showed prolonged rescue of scPCP-induced NOR deficit. a–c The effect of vehicle, scPCP, and scTPA-023 (2 mg/kg; i.p.; 7 days; days 0–7) + scPCP (10 mg/kg; i.p.; b.i.d.; 7 days; days 0–7) 30 min after scTPA-023 injections on NOR on AT, RT, and DI in scPCP-treated male C57BL/6J mice. Data are shown as mean ± S.E.M. of exploration time (s) n = 10 mice per group. For the scPCP and scVeh groups, the average for all the weeks they were tested, calculated, and reported as a single histogram bar. a AT—no significant difference in the exploration of left and right object between the groups; b RT—**P < 0.01; ***P < 0.001—significant exploration of novel vs familiar object; c DI—***p < 0.001—significant reduction in DI vs vehicle-treated controls; ###P < 0.001—significant increase in DI vs scPCP-treated C57BL/6J mice; ^^^P < 0.001: significant decrease in DI vs scTPA-023+scPCP week 6. d–f The effect of vehicle, scPCP, and scPCP (10 mg/kg; i.p.; b.i.d.; 7 days; days 0–7; followed by 7 days washout) + scTPA-023 (2 mg/kg; i.p.; 7 days; days 15–21) on NOR on AT, RT, and DI in scPCP-treated male C57BL/6J mice. Data are shown as mean ± S.E.M. of exploration time (s) n = 10 mice per group. For the scPCP and scVeh groups, the average for all the weeks they were tested, calculated, and reported as a single histogram bar. a AT—no significant difference in the exploration of left and right object between the groups; b RT—***p < 0.001—significant exploration of novel vs familiar object; c DI—***p < 0.001—significant reduction in DI vs vehicle-treated controls; ###P < 0.001—significant increase in DI vs scPCP-treated C57BL/6J mice; ^^^P < 0.001: significant decrease in DI vs scPCP+scTPA-023 (week 1)
